

Exhibit A
Amgen's Response to Documents Roche Claims As Prior Art (Category A)

Exhibit Letter	DOC_DATE	DESCRIPTION	AMGEN'S POSITION
VF	00/00/1983	Ascensao et al., "Erythropoietin Production by a Human Testicular Germ Cell Line," Blood 62(5): 1132-34 (1983)	<ul style="list-style-type: none"> No foundation as to how exhibit relates to Roche's claims of invalidity and therefore the exhibit is confusing and prejudicial.
VI	00/00/1981	Babel et al., "Amino Acid Sequence Determination of the ADP, ATP Carrier from Beet Heart Mitochondria - The Sequence of the C-Terminal Acidolytic Fragment," Biochimica et Biophysica Acta 670: 176-180 (1981)	<ul style="list-style-type: none"> No foundation as to how exhibit relates to Roche's claims of invalidity and therefore the exhibit is confusing and prejudicial; Offered during examination of Dr. Lowe but court denied request to admit because it was not in Lowe's report
VP	00/00/1981	Beaucage et al. (1981) "Deoxynucleoside Phosphoramidites--A new Class of Key Intermediates for Deoxypolynucleotide Synthesis," Tetrahedron Letters, 22(20), 1859-1862 (1981)	<ul style="list-style-type: none"> No foundation as to how exhibit relates to Roche's claims of invalidity and therefore the exhibit is confusing and prejudicial;
CVM - QGE	00/00/1983	Farber and Zanjani, "Translation of mRNA from Human Kidneys into Biologically Active Erythropoietin Following Microinjection into Xenopus Laevis Oocytes," Blood 62(5) (Supp. 1):122a, Abstract No. 392 (1983).	<ul style="list-style-type: none"> No foundation as to how exhibit relates to Roche's claims of invalidity and therefore the exhibit is confusing and prejudicial.
NAY	8/20/1981	Edge et al. "Total synthesis of a human leukocyte interferon gene," Nature 292(5825): 756-62 (1981)	<ul style="list-style-type: none"> No foundation as to how exhibit relates to Roche's claims of invalidity and therefore the exhibit is confusing and prejudicial.
NAZ	00/00/1983	Edge, M.D., et al. (1983) "Chemical synthesis of a human interferon-alpha 2 gene and its expression in Escherichia coli," Nucleic Acids Res. 11(18):5419-35 (1983)	<ul style="list-style-type: none"> No foundation as to how exhibit relates to Roche's claims of invalidity and therefore the exhibit is confusing and prejudicial.
NCS	07/00/1983	Farber and Zanjani, "Translation of mRNA from Human Kidneys into Biologically Active Erythropoietin Following Microinjection into Xenopus Laevis Oocytes," Exp Hematol. 11 (S14): 57 (1983)	<ul style="list-style-type: none"> No foundation as to how exhibit relates to Roche's claims of invalidity and therefore the exhibit is confusing and prejudicial.
NFC	00/00/1983	Glanville et al., "Completion of the amino acid sequence of the alpha chain from type I calf skin collagen," The Biochem. J. 215: 183-189 (1983)	<ul style="list-style-type: none"> No foundation as to how exhibit relates to Roche's claims of invalidity and therefore the exhibit is confusing and prejudicial.
NYW	9/10/1981	Thomas et al., "The Amino Acid Sequence of the gamma-Subunit of Mouse Submaxillary Gland 7 S Nerve Growth Factor," The Journal of Biological Chemistry 256(17): 9156-9166 (1981)	<ul style="list-style-type: none"> No foundation as to how exhibit relates to Roche's claims of invalidity and therefore the exhibit is confusing and prejudicial; Not identified by Roche under 35 U.S.C. § 282 as a notice of prior art.
PRX	10/17/1983	Erythropoietin Presentation to Chugai Pharmaceutical Company, Genetics Institute, October 17, 1983	<ul style="list-style-type: none"> The document is a random presentation and there is no foundation as to how it relates to the claims of validity and therefore the exhibit is confusing and prejudicial; not identified by Roche under 35 U.S.C. §282 as a notice of prior art.

Exhibit A
Amgen's Response to Documents Roche Claims As Prior Art (Category A)

Exhibit Letter	DOC DATE	DESCRIPTION	AMGEN'S POSITION
QCG	8/14/2001	U.S. Patent 6,274,335	<ul style="list-style-type: none"> No foundation as to how exhibit relates to Roche's claims of invalidity and therefore the exhibit is confusing and prejudicial. Also, not identified by Roche under 35 U.S.C. 282 as a notice of prior art.
QCH	8/30/2005	U.S. Patent 6,936,695	<ul style="list-style-type: none"> No foundation as to how exhibit relates to Roche's claims of invalidity and therefore the exhibit is confusing and prejudicial. Also, not identified by Roche under 35 U.S.C. 282 as a notice of prior art.
NMY	12/00/1978	Lawn et al. (1978) "The Isolation and Characterization of Linked, delta- and beta-Globin Genes from a Cloned Library of Human DNA," Cell, 15, 1157-1174 (Dec. 1978)	<ul style="list-style-type: none"> No foundation as to how exhibit relates to Roche's claims of invalidity and therefore the exhibit is confusing and prejudicial; not identified by Roche under 35 U.S.C. §282 as a notice of prior art
NZR	7/1/1980	Uriaub and Chasin, "Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity," PNAS 77: 4216-4220 (1980)	No foundation as to how exhibit relates to Roche's claims of invalidity and therefore the exhibit is confusing and prejudicial; Not identified by Roche under 35 U.S.C. §282 as a notice of prior art
PPK		(Fritsch Deposition Ex. 188) Collaboration Agreement between T. Miyake and Genetics Institute (signed)	No objection.
QCU	9/24/2002	U.S. Patent 6,455,275	<ul style="list-style-type: none"> No foundation as to how exhibit relates to Roche's claims of invalidity and therefore confusing and prejudicial. Also, not identified by Roche under 35 U.S.C. 282 as a notice of prior art.
OFD		Handwritten notes (Fritsch deposition ex. 194)	<ul style="list-style-type: none"> See Amgen's MIL, Docket Number 1034, which reflects that this document is not prior 102(g) art; No foundation as to how exhibit relates to Roche's claims of invalidity and therefore confusing and prejudicial; the document is a handwritten note not authored by the deponent and accordingly cannot be authenticated.

Exhibit A
Amgen's Response to Documents Roche Claims As Prior Art (Category A)

Exhibit Letter	DOC_DATE	DESCRIPTION	AMGEN'S POSITION
OHV	12/14/1983	Notebook 193 (Edward Fritsch) (Fritsch deposition ex. 48)	<ul style="list-style-type: none"> • See Amgen's MIL, Docket Number 1034, which reflects that this document is not prior 102(g) art; • No foundation as to how exhibit relates to Roche's claims of invalidity and therefore the exhibit is confusing and prejudicial
QEI		(Fritsch Depo Ex. 5) Memorandum from K. Smith to Genetics Institute Distribution List re: EPO Clone/Chugai (Fritsch deposition ex. 5)	<ul style="list-style-type: none"> • See Amgen's MIL, Docket Number 1034, which reflects that this document is not prior 102(g) art • No foundation as to how exhibit relates to Roche's claims of invalidity and therefore the exhibit is confusing and prejudicial; • not properly authenticated by deposition testimony; • not disclosed on Roche Exhibit List
OJC	00/00/1985	Notebook(redacted) (Fritsch deposition ex. 55)	<ul style="list-style-type: none"> • See Amgen's MIL, Docket Number 1034, which reflects that this document is not prior 102(g) art; • No foundation as to how exhibit relates to Roche's claims of invalidity and therefore the exhibit is confusing and prejudicial; • Not properly authenticated by deponent because it is not clear that notebook is his.
QEI		(Fritsch Depo Ex. 12) Cover Letter from Katherine Smith to Misao Aihara with attached EPO Quarterly Report	<ul style="list-style-type: none"> • See Amgen's MIL, Docket Number 1034, which reflects that this document is not prior 102(g) art; • No foundation as to how exhibit relates to Roche's claims of invalidity and therefore the exhibit is confusing and prejudicial <ul style="list-style-type: none"> • Not disclosed on Roche Exhibit List; Letter not authored by deponent and not authenticated by deponent
OIC	7/16/1984	Notebook 316 (Richard Wright) (Fritsch deposition ex. 222 part 1)	<ul style="list-style-type: none"> • See Amgen's MIL, Docket Number 1034, which reflects that this document is not prior 102(g) art; • No foundation as to how exhibit relates to Roche's claims of invalidity and therefore the exhibit is confusing and prejudicial • Witness did not authenticate lab notebook of Richard Wright.
QEK		(Fritsch Depo Ex. 222 part 2) Notebook 316 (Richard Wright)	<ul style="list-style-type: none"> • See Amgen's MIL, Docket Number 1034, which reflects that this document is not prior 102(g) art; • No foundation as to how exhibit relates to Roche's claims of invalidity and therefore the exhibit is confusing and prejudicial • Witness did not authenticate lab notebook of Richard Wright; Not Disclosed on Roche Exhibit List
PJY	4/20/1988	Goldwasser Grant Application re Erythropoietin: Purification Properties Biogenesis	<ul style="list-style-type: none"> • Not 102(g) prior art; • Roche did not attempt to authenticate through testimony of Eugene Goldwasser; • No foundation as to how exhibit relates to Roche's claims of invalidity and therefore the exhibit is confusing and prejudicial

Exhibit A
Amgen's Response to Documents Roche Claims As Prior Art (Category A)

Exhibit Letter	DOC_DATE	DESCRIPTION	AMGEN'S POSITION
PVJ-1		Goldwasser Grant Application re Erythropoietin: Purification Properties Biogenesis	Not 102(g) prior art; • Roche did not attempt to authenticate through testimony of Eugene Goldwasser; • No foundation as to how exhibit relates to Roche's claims of invalidity and therefore the exhibit is confusing and prejudicial; Unnecessary subset of P.JY.
PJY-2	4/00/1983	Goldwasser Grant Application re Erythropoietin: Purification Properties Biogenesis	Not 102(g) prior art; • Roche did not attempt to authenticate through testimony of Eugene Goldwasser; • No foundation as to how exhibit relates to Roche's claims of invalidity and therefore the exhibit is confusing and prejudicial; Unnecessary subset of P.JY.
PJY-3	4/00/1982	Goldwasser Grant Application re Erythropoietin: Purification Properties Biogenesis	Not 102(g) prior art; • Roche did not attempt to authenticate through testimony of Eugene Goldwasser; • No foundation as to how exhibit relates to Roche's claims of invalidity and therefore the exhibit is confusing and prejudicial; Unnecessary subset of P.JY.
PJY-4	03/00/1981	Goldwasser Grant Application re Erythropoietin: Purification Properties Biogenesis	Not 102(g) prior art; • Roche did not attempt to authenticate through testimony of Eugene Goldwasser; • No foundation as to how exhibit relates to Roche's claims of invalidity and therefore the exhibit is confusing and prejudicial; Unnecessary subset of P.JY.
PJY-5	4/00/1980	Goldwasser Grant Application re Erythropoietin: Purification Properties Biogenesis	Not 102(g) prior art; • Roche did not attempt to authenticate through testimony of Eugene Goldwasser; • No foundation as to how exhibit relates to Roche's claims of invalidity and therefore the exhibit is confusing and prejudicial; Unnecessary subset of P.JY.
PJY-6	8/00/1979	Goldwasser Grant Application re Erythropoietin: Purification Properties Biogenesis	Not 102(g) prior art; • Roche did not attempt to authenticate through testimony of Eugene Goldwasser; • No foundation as to how exhibit relates to Roche's claims of invalidity and therefore the exhibit is confusing and prejudicial; Unnecessary subset of P.JY.
PVJ-7	00/00/1978	Goldwasser Grant Application re Erythropoietin: Purification Properties Biogenesis	Not 102(g) prior art; • Roche did not attempt to authenticate through testimony of Eugene Goldwasser; • No foundation as to how exhibit relates to Roche's claims of invalidity and therefore the exhibit is confusing and prejudicial; Unnecessary subset of P.JY.
RO	1/5/1999	US Patent 5,856,298	• No foundation as to how exhibit relates to Roche's claims of invalidity and therefore confusing and prejudicial. Also, not identified by Roche under 35 U.S.C. 282 as a notice of prior art.